August 2026 · 9 min read
You need to assess whether your drug candidate interacts with an ABC efflux transporter. Three in vitro methods are available: the vesicular transport assay, the cell-based monolayer assay, and the ATPase assay. Each works — but each has a specific permeability window, throughput profile, and regulatory acceptance level that makes it the right choice for some compounds and the wrong choice for others.
This guide explains exactly when to use which — with a decision framework you can apply directly to your compound series.
The three methods — a brief overview
All three assay formats are designed to detect interactions between a drug candidate and an ABC transporter. They differ in how they measure that interaction.
Vesicular transport assay (membrane vesicle assay)
Inside-out membrane vesicles are prepared from insect cells (typically Sf9) or mammalian cells (HEK293) that overexpress a specific ABC transporter. During the preparation process, the membrane is inverted — placing the substrate-binding site of the transporter on the outside of the vesicle. When ATP is added, the transporter actively pumps its substrate into the interior of the vesicle. The amount of substrate accumulated inside the vesicle — measured after rapid filtration — is the direct readout of transporter activity.
Inhibition is measured by adding a test compound alongside the probe substrate and quantifying the reduction in vesicular accumulation. In a vesicular transport setting, passive permeability of the compound does not affect apparent inhibitory potential — a critical advantage over cell-based assays for lipophilic compounds.
Cell-based monolayer assay (bidirectional transport)
Polarised cell monolayers — typically Caco-2, MDCKII-MDR1, or LLC-MDR1 — are grown on permeable filter inserts. The compound is applied to either the apical (A) or basolateral (B) compartment, and transport in both directions is measured after a defined incubation period. An efflux ratio (B→A / A→B) greater than 2 indicates active transporter involvement. The ratio is reduced in the presence of a selective inhibitor to confirm transporter specificity.
ATPase assay
ABC transporters hydrolyse ATP to power substrate translocation. The ATPase assay measures this hydrolysis indirectly by quantifying the inorganic phosphate (Pi) released. Transported substrates increase baseline ATPase activity, while inhibitors or slowly transported compounds inhibit baseline ATPase activity and/or the ATPase activity measured in the presence of a stimulating agent — allowing the assay to determine whether a compound acts as a substrate and/or inhibitor.
The permeability problem — why it determines your method
The most important variable in ABC transporter assay method selection is the passive permeability of your compound. This is not optional guidance — it directly determines whether your assay will generate meaningful data or artefactual results.
- High permeability compounds (logP >3, Papp >20 × 10⁻⁶ cm/s): In a cell-based assay, these compounds cross the monolayer so rapidly by passive diffusion that efflux transporter activity is masked — the efflux ratio is compressed toward 1.0 regardless of transporter interaction. The vesicular transport assay avoids this problem entirely because passive permeability of the compound does not affect apparent inhibitory potential in a vesicular transport setting.
- Low permeability compounds (logP <1, Papp <2 × 10⁻⁶ cm/s): In the vesicular transport assay, these compounds may accumulate inside vesicles through non-specific trapping rather than active transport — creating false positive substrate results. The cell-based assay is more appropriate here because the intact cell provides a physiologically relevant barrier.
- Medium permeability compounds: Both assays perform reliably. Method choice is driven by throughput, regulatory context, and the specific transporter being studied.
Full comparison — vesicular transport vs. cell-based vs. ATPase
| Parameter | Vesicular Transport | Cell-Based Monolayer | ATPase |
|---|---|---|---|
| Principle | Active accumulation into inside-out vesicles (ATP-dependent) | Bidirectional transport across cell monolayer (efflux ratio) | Measurement of ATP hydrolysis (Pi release) |
| Best compound permeability | Low to medium | Medium; problematic for very high or very low Papp | Any — permeability-independent |
| Detects substrate? | Yes (direct format with radiolabel or LC-MS) | Yes (efflux ratio >2) | Yes (ATPase activation) |
| Detects inhibitor? | Yes (IC50 in inhibitory format) | Yes (efflux ratio reduction) | Yes (ATPase inhibition) |
| Throughput | Medium-high (96-well, same-day IC50) | Low-medium (4–21 day cell growth required) | High (colorimetric, simple readout) |
| Turnaround | Same day — membranes stored at −80°C indefinitely and thawed on demand | Days to weeks (cell culture preparation) | Same day |
| FDA/EMA regulatory acceptance | Accepted for BSEP, MRP2–4, P-gp, BCRP | Preferred for P-gp and BCRP substrate identification | Accepted as supporting data; not standalone for DDI submission |
| Effect of P-gp expression level | IC50 independent of transporter expression level | IC50 depends on transporter expression — source-dependent variability | Depends on membrane preparation quality |
| Suitable for | BSEP, MRP2, MRP3, MRP4, MRP5, MRP8, BCRP, P-gp | P-gp (MDR1), BCRP — substrate studies | P-gp (ABCB1), BCRP — early screening |
| Limitation | False positives for highly permeable compounds in substrate assay | Not suitable for high Papp compounds; long setup time | Nonlinear relationship between ATPase activity and transport rate; not standalone for regulatory submission |
| Cost | Low-medium per sample | Medium-high (cell culture infrastructure) | Low (colorimetric, simple equipment) |
Which transporters require which method?
Not all transporters can be studied with all three methods. The transporter’s biology and its expression system determine which assay format is technically feasible.
| Transporter | Gene | Recommended method | Why |
|---|---|---|---|
| BSEP | ABCB11 | Vesicular transport | Hepatocyte-specific; no reliable cell monolayer model. Vesicle assay is FDA/EMA standard for BSEP/DILI assessment |
| MRP2 | ABCC2 | Vesicular transport | Inside-out vesicles provide clean assay window; vacuum filtration system offers rapid and reliable means for screening drug candidates for DILI risk |
| MRP3, MRP4 | ABCC3, ABCC4 | Vesicular transport | No standard cell monolayer model; vesicle assay is the practical option |
| P-gp (MDR1) | ABCB1 | Cell-based (substrate) or vesicular (inhibitor/high Papp) | FDA prefers cell-based for substrate ID; vesicular transport preferred for high permeability compounds where efflux ratio is compressed |
| BCRP | ABCG2 | Cell-based (substrate) or vesicular (inhibitor) | Several BCRP substrates and inhibitors are of low passive permeability, and the vesicular transport assay works well in this permeability space |
| MRP1, MRP5, MRP8 | ABCC1, ABCC5, ABCC8 | Vesicular transport | No standard cell model; vesicle kits from Cell4Pharma available |
The decision framework — step by step
Apply these four questions in sequence to select the right assay for your compound:
- Which transporter are you studying?
If BSEP, MRP2, MRP3, MRP4, MRP5, MRP8 → vesicular transport assay only (no cell model available).
If P-gp or BCRP → continue to question 2. - What is the passive permeability of your compound?
Papp <5 × 10⁻⁶ cm/s (low) → vesicular transport or cell-based both valid; vesicular preferred for throughput.
Papp >20 × 10⁻⁶ cm/s (high) → vesicular transport only; cell-based will give false-negative efflux ratio.
Medium Papp → both valid; continue to question 3. - Substrate or inhibitor study?
Substrate identification → cell-based monolayer preferred (FDA guidance for P-gp/BCRP).
Inhibitor IC50 → vesicular transport assay preferred (expression-independent IC50, same-day turnaround). - What is your regulatory context?
IND-enabling DMPK package → use FDA/EMA-accepted methods per transporter (see table above).
Early discovery screening → ATPase assay acceptable as high-throughput rank-ordering tool.
DILI risk assessment (BSEP/MRP2) → vesicular transport assay required.
The ATPase assay: useful — but not standalone
The ATPase assay is valuable for early-phase high-throughput screening when you need to rank-order a large compound series for transporter interaction quickly and cheaply. It requires no specialised equipment beyond a plate reader and generates same-day results.
Its limitations are important to understand: ATPase assays are challenged by the nonlinear relationship of ATPase activity and transport rate. This means that ATPase activation does not linearly predict transport rate, and ATPase inhibition at high compound concentrations can occur through mechanisms unrelated to transporter inhibition (e.g. non-specific membrane effects). For regulatory DDI submissions, the ATPase assay is accepted as supporting data but is not sufficient as a standalone method for P-gp or BCRP interaction characterisation.
The correct workflow: use the ATPase assay to filter your compound series early, then confirm hits with vesicular transport or cell-based assay as appropriate for regulatory submission.
Ready-to-use vesicle kits for in-house DMPK
Running vesicular transport assays in-house has historically required significant infrastructure for membrane preparation. Ready-to-use vesicle kits eliminate this barrier — pre-prepared, quality-controlled inside-out membrane vesicles that simply need to be thawed before use.
SeamlessBio distributes the Cell4Pharma ABC Transporter Vesicle Kit series for in-house DMPK testing across the full panel of clinically relevant efflux transporters:
- BSEP Vesicle Kit — bile salt export pump; DILI risk assessment per FDA/EMA guidance
- P-gp Vesicle Kit — MDR1/ABCB1; high Papp compound inhibition studies
- BCRP Vesicle Kit — ABCG2; low permeability substrate/inhibitor studies
- MRP1 Vesicle Kit — ABCC1
- MRP2 Vesicle Kit — ABCC2; hepatic efflux, cholestasis risk
- MRP3 Vesicle Kit — ABCC3
- MRP4 Vesicle Kit — ABCC4
- MRP5 Vesicle Kit — ABCC5
- MRP8 Vesicle Kit — ABCC8
- Control Vesicle Kit — non-transfected membrane control for background subtraction
Each kit contains 100 reactions, validated probe substrates, ATP regenerating system, and assay buffer. Membranes stored at −80°C; stable for 12 months. Full assay protocol and QC data included.
→ View the full Cell4Pharma kit portfolio at SeamlessBio
Summary — the three-line decision rule
- BSEP, MRP2–5, MRP8: vesicular transport assay — no cell model available, this is your only option
- P-gp or BCRP substrate: cell-based monolayer — FDA/EMA preferred for substrate identification
- P-gp or BCRP inhibitor, high Papp compound, or IND-enabling IC50: vesicular transport assay — expression-independent, same-day, regulatory-accepted
Further reading on seamlessbio.de:
- BSEP Inhibition & DILI — From Vesicle Assay to High-Throughput Screening
- Cell4Pharma ABC Transporter Vesicle Kit Portfolio
- CRO & Contract Research — DMPK Supply Guide
Questions about kit selection for your compound or assay setup? Contact us at info@seamlessbio.de or request a quote.
English 
Deutsch